Matt Phipps
Stock Analyst at William Blair
(0.11)
# 3,300
Out of 4,413 analysts
12
Total ratings
22.22%
Success rate
-46.36%
Average return
Main Sectors:
Top Industries:
12 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGEM Cullinan Oncology | Initiates: Outperform | n/a | $28.10 | - | 1 | Apr 15, 2024 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Market Perform | n/a | $44.21 | - | 1 | Oct 27, 2023 | |
| KZR Kezar Life Sciences | Downgrades: Market Perform | n/a | $0.84 | - | 1 | Mar 16, 2023 | |
| JANX Janux Therapeutics | Initiates: Outperform | n/a | $58.19 | - | 1 | Nov 14, 2022 | |
| GMAB Genmab | Initiates: Market Perform | n/a | $28.75 | - | 1 | Nov 14, 2022 | |
| ALRN Aileron Therapeutics | Downgrades: Market Perform | n/a | $4.16 | - | 1 | Jun 29, 2022 | |
| INKT MiNK Therapeutics | Initiates: Outperform | n/a | $0.95 | - | 1 | Nov 9, 2021 | |
| CALA Calithera Biosciences | Downgrades: Market Perform | n/a | $0.02 | - | 1 | Nov 5, 2021 | |
| TPST Tempest Therapeutics | Initiates: Outperform | n/a | $3.62 | - | 1 | Oct 21, 2021 | |
| JSPR Jasper Therapeutics | Initiates: Outperform | n/a | $23.99 | - | 1 | Oct 21, 2021 | |
| BIIB Biogen | Upgrades: Outperform | n/a | $216.13 | - | 1 | Jun 8, 2021 | |
| MRUS Merus | Initiates: Outperform | n/a | $47.02 | - | 1 | Apr 8, 2021 |
Cullinan Oncology
Apr 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $28.10
Upside: -
Bristol-Myers Squibb Company
Oct 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $44.21
Upside: -
Kezar Life Sciences
Mar 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.84
Upside: -
Janux Therapeutics
Nov 14, 2022
Initiates: Outperform
Price Target: n/a
Current: $58.19
Upside: -
Genmab
Nov 14, 2022
Initiates: Market Perform
Price Target: n/a
Current: $28.75
Upside: -
Aileron Therapeutics
Jun 29, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $4.16
Upside: -
MiNK Therapeutics
Nov 9, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.95
Upside: -
Calithera Biosciences
Nov 5, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $0.02
Upside: -
Tempest Therapeutics
Oct 21, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.62
Upside: -
Jasper Therapeutics
Oct 21, 2021
Initiates: Outperform
Price Target: n/a
Current: $23.99
Upside: -
Biogen
Jun 8, 2021
Upgrades: Outperform
Price Target: n/a
Current: $216.13
Upside: -
Merus
Apr 8, 2021
Initiates: Outperform
Price Target: n/a
Current: $47.02
Upside: -